Solid Biosciences SLDB shares are trading higher on Friday after the company and Ultragenyx announced a strategic collaboration and license agreement to focus on the development and commercialization of new gene therapies for Duchenne muscular dystrophy.
Solid Biosciences is a life science company. It is engaged in manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age.
Solid Biosciences shares traded up 3.50% to $3.55 on Friday at the time of publication. The stock has a 52-week high of $12.84 and a 52-week low of $1.93.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
